NR4A1 and breast carcinoma: DAWNA-1 was a phase III, randomised (1:2), double-blind, placebo-controlled clinical trial which included 361 women with advanced breast cancer, positive hormone receptors, and HER-2 negative whose disease had progressed after receiving two lines of endocrine therapy prior to inclusion in the study.